Human Pharma Nonclinical Development Support
A practical way to move from an open development question to a workable nonclinical plan.
KGAH-ONE works with Human Pharma and biopharma teams that need to compare models, endpoints, assays, or specialist providers before a study is fully defined. We help frame the question, identify realistic options, and bring the right scientific expertise into the discussion.
Start with the problem you need to solve.
A provider or model may already be in mind—or it may still be open. Either way, the first step is to be clear about what the next study needs to tell you.
Work through the choices that come before a nonclinical study.
KGAH-ONE is useful when the scientific question is clear but the best route is not—or when several providers and capabilities need to be considered together.
Choose around the biology
Compare disease context, intervention timing, pathology, biomarkers, and functional or molecular readouts.
Turn the question into a study
Clarify groups, comparators, timing, samples, endpoints, and the evidence package needed for the next decision.
Bring in the right expertise
Connect with CROs, research institutions, pathology groups, analytical providers, or technical specialists as needed.
Keep the work moving
Coordinate technical discussions, feasibility checks, timelines, and commercial steps without losing the original development context.
From the first question to a defined next step.
Frame the question
Start with the disease, modality, mechanism of action, development stage, what is already known, and what is still uncertain.
Review the options
Look at model fit, endpoints, pathology, assays, timing, comparator design, and other possible evaluation routes.
Talk to the right specialists
Bring the relevant scientific teams into the discussion when technical depth or feasibility input is needed.
Define the next action
Move toward a pilot, study scope, proposal, additional validation, or another practical development step.
Representative areas where we can help structure the nonclinical pathway.
The appropriate model, endpoint package, and research partner depend on the individual program. These are current areas of focus, not a fixed study catalogue.
MASH / MASLD
Disease stage, metabolic background, fibrosis, pathology, model fit, and endpoint planning.
Kidney / CKD
Renal function, injury, fibrosis, pathology, biomarkers, and model selection across different mechanisms.
Pulmonary Fibrosis
Acute versus chronic settings, intervention timing, histopathology, molecular readouts, and fibrosis-focused evaluation.
Oncology
Tumor biology, treatment response, pathology, immune readouts, and appropriate preclinical evaluation routes.
Tailor-Made Evaluation
Feasibility, pilot design, model establishment, or a customized route when an established approach is not enough.
One place to start, without locking the program into one provider.
The value of KGAH-ONE is not simply an introduction. It is having one coordinating point that keeps the development question in view while different scientific options are considered.
One point of contact
Instead of starting separate conversations with multiple providers, begin with the development question and narrow the route from there.
A wider view of the options
Compare different model, pathology, assay, and specialist routes before deciding which combination best fits the program.
Direct scientific discussion
When technical depth is needed, your team can speak directly with the relevant scientists or specialists.
Continuity across the work
KGAH-ONE keeps the original question, decision criteria, and next step aligned even when more than one partner is involved.
Access the capability that fits the work.
KGAH-ONE works across a network of specialized research organizations and technical experts. Depending on the program, that may include disease-model CROs, research institutions, pathology laboratories, analytical providers, or other specialist groups.
We do not need to sit between your team and the science. Where it makes sense, technical discussions can take place directly with the relevant specialists while KGAH-ONE supports coordination and the commercial process.
Start the conversation without disclosing sensitive details.
An initial discussion can stay at a non-confidential level. You can tell us the indication, modality, development stage, and the question you need answered without sharing proprietary data.
Share more only when it is needed.
If a useful next step requires confidential information, the appropriate confidentiality arrangements can be put in place before those details are discussed or shared with a specialist partner.
Tell us what you are trying to work through.
If the next nonclinical step is not obvious—or if several routes need to be compared—KGAH-ONE can help organize the options and bring the right expertise into the discussion.